Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 4/20 | 0.51 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.51 |
| ▸ | TET3 | O43151 | 1/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.48 |
| ▸ | ASPH | Q12797 | 1/20 | 0.48 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.48 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.48 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480525 | 0.85 | VEGFA (0.51) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL3480464 | 0.83 | EGLN1 (0.62) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL29772996 | 0.82 | EGLN1 (0.51) | VEGFAFLT1EGLN1EGLN3LATS1 | |
| SCHEMBL3041653 | 0.82 | EGLN1 (0.51) | VEGFAFLT1EGLN1EGLN3LATS1 | |
| SCHEMBL1921393 | 0.80 | EGLN1 (0.56) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL29771346 | 0.80 | VEGFA (0.53) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL1921660 | 0.80 | VEGFA (0.53) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL1921290 | 0.79 | VEGFA (0.49) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL3480617 | 0.78 | VEGFA (0.48) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL14122489 | 0.74 | EGLN1 (0.67) | VEGFAFLT1EGLN1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | VEGFA 117/4885FLT1 55/4885EGLN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.